The recent findings of significant cardiac risks with longterm use of the selective COX-2 inhibitors and naproxen leave many patients without access to drugs they may depend on for sustained management of pain. These cardiac risks can arise from disturbances in the ratio of prostacyclin and thromboxane A-2. Integrative medicine offers a variety of interventions that do not disrupt this ratio, including herbs, nutriceuticals, mind-body strategies, and physical care. Clinical studies for evaluating these interventions, and research on sustainable production of those that are natural substances, should be given greater funding priority at this time.
Research and markets: despite the withdrawal of Vioxx— rofecoxib—from the market in November 2004, considerable activity continues to be reported relating to the development of COX-2 inhibitors. Available at: http://www.pharmacytimes.com/newsfeed.cfm?id=23619. Accessed December 27, 2004.
2.
Ellis C. Anti-inflammatories: heart of the matter. Available at: http://www.signaling-gateway.org/update/updates/200206/nrd816.html. Accessed December 27, 2004.
3.
Capone ML, Taconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109: 1468-1468.
4.
Soeken KL. Selected CAM therapies for arthritis related pain: the evidence fromsystematic reviews. Clin J Pain. 2004;20:13-18.
5.
Ernst E. Manual therapies for pain control: chiropractic and massage. Clin J Pain. 2004;20:8-12.
6.
Tall JM, Raja SR. Dietary constituents as novel therapies for pain. Clin J Pain. 2004;20:19-26.
7.
Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3-7.
8.
Astin JA. Mind-body therapies for the management of pain. Clin J Pain. 2004;20:27-32.
9.
Zhao C, Wacnik PW, Tall JM, et al. Analgesic effects of a soycontaining diet in three murine bone cancer pain models. J Pain. 2004;5:104-110.
10.
Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7-37.
11.
Streffer JR, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology. 2001;56:1219-1221.
12.
Jho DH, Cole SM, Lee EM, Espat NJ. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther. 2004;3:98-111.
13.
Takahata K, Yamanaka M. PGI3 production from eicosapentaenoic acid in 3T3 fibroblast cells and cultured bovine pulmonary artery endothelial cells. Thromb Res. 1987;45:581-589.
14.
Fischer S, Weber PC. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983;116:1091-1099.
15.
Kobzar G, Mardla V, Jarving I, Samel N. Comparison of antiaggregatory effects of PGI2, PGI2 and iloprost on human and rabbit platelets. Cell Physiol Biochem. 2001;11:279-284.
16.
Richter WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res. 2003;20:332-336.
17.
Yzebe D, Lievre M. Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. Fundam Clin Pharmacol. 2004;18:581-592.
18.
Singer P, Wirth M. Can n-3 PUFAs reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids. 2004;71:153-159.
19.
Alternative sources of fish oil and fishmeal. Available at: http://www.rspb.org.uk/policy/marine/fisheries/sustainable/alternatives.asp. Accessed December 27, 2004.
